Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Membranous Glomerulonephritis: A Retrospective Study on Prognostic Outcome

Version 1 : Received: 17 February 2022 / Approved: 18 February 2022 / Online: 18 February 2022 (14:49:32 CET)

How to cite: Maifata, S.; Abd Ghani, F.; Hod, R.; Zakaria, N.F. Membranous Glomerulonephritis: A Retrospective Study on Prognostic Outcome. Preprints 2022, 2022020237 (doi: 10.20944/preprints202202.0237.v1). Maifata, S.; Abd Ghani, F.; Hod, R.; Zakaria, N.F. Membranous Glomerulonephritis: A Retrospective Study on Prognostic Outcome. Preprints 2022, 2022020237 (doi: 10.20944/preprints202202.0237.v1).

Abstract

Background: Membranous glomerulonephritis (MGN) is one of the most common causes of nephrotic syndrome in non-diabetic adults, accounting for up to one-third of biopsy diagnostics in some regions. A watchful waiting strategy has been adopted to accurately assess the success of MGN. In this study, we predict prognostic risk factors for primary MGN patients for effective intervention and prognosis. Materials and Methods: This is a retrospective study design involving 125 biopsy-proven MGN subjects on follow-up from January 2012 to October 2019 in Hospital Serdang and Hospital Kuala Lumpur, Malaysia. Result and Conclusion: After the median follow-up of 36 (15.0-57.0) months, 26 (20.8%) consisting of 17 (13.6%) primary MGN and 9 (7.2%) secondary MGN subjects achieved complete remission while 17 (13.6%) and 10 (8.0%) of primary and secondary MGN subjects respectively achieved spontaneous remission. Subjects with nephrotic range proteinuria have 2.917 odds more at risk of primary MGN while subjects with hypertension have 2.417 odds risk of primary MGN compared to those with no hypertension at presentation. Multiple logistic regression models retained only factors directly associated with MGN with only nephrotic range proteinuria associated with primary MGN. Those with nephrotic range proteinuria were 3.04 times the odds of primary MGN when compared with those without nephrotic syndrome (95% C. I = 1.089, 8.472). The nephrotic syndrome could be used to determine the prognosis in patients with primary MGN especially those at risk of end-stage kidney disease.

Keywords

Membranous glomerulonephritis; remission; nephrotic syndrome; chronic kidney disease; end-stage kidney diseases

Subject

MEDICINE & PHARMACOLOGY, General Medical Research

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.